SecSonar.com

Crescent Biopharma, Inc. (CBIO)

Crescent Biopharma, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Crescent Biopharma, Inc. (CBIO) is a Biotechnology company based in US with a market capitalization of $598.3M. Free cash flow was negative at -$72.5M. This page tracks CBIO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 41 employees · IPO Jan 10, 2014

Valuation

Valuation & price

$19.97 · as of May 17, 2026 · -26.0% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.95

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$26.98$17.96$8.94Jul 25Dec 25Jul 26Jul 7, 25$15.29Jul 9, 25$14.79Jul 11, 25$12.96Jul 15, 25$11.75Jul 17, 25$13.02Jul 21, 25$13.20Jul 23, 25$13.18Jul 25, 25$13.29Jul 29, 25$12.30Jul 31, 25$12.42Aug 4, 25$11.84Aug 6, 25$11.00Aug 11, 25$12.90Aug 13, 25$13.90Aug 15, 25$13.79Aug 19, 25$13.60Aug 21, 25$14.40Aug 25, 25$14.70Aug 27, 25$14.25Aug 29, 25$14.40Sep 3, 25$13.23Sep 5, 25$14.24Sep 9, 25$12.55Sep 11, 25$12.55Sep 16, 25$12.50Sep 18, 25$12.94Sep 22, 25$13.11Sep 24, 25$12.98Sep 26, 25$12.43Sep 30, 25$11.89Oct 2, 25$12.03Oct 6, 25$11.60Oct 8, 25$12.06Oct 10, 25$11.35Oct 14, 25$10.39Oct 16, 25$12.35Oct 21, 25$12.65Oct 23, 25$12.79Oct 27, 25$13.00Oct 29, 25$12.50Oct 31, 25$12.75Nov 4, 25$12.44Nov 6, 25$13.10Nov 10, 25$13.11Nov 12, 25$13.05Nov 14, 25$13.02Nov 18, 25$13.00Nov 20, 25$13.08Nov 25, 25$14.00Nov 28, 25$15.05Dec 2, 25$13.09Dec 4, 25$12.99Dec 8, 25$13.17Dec 10, 25$14.49Dec 12, 25$14.09Dec 16, 25$12.92Dec 18, 25$12.22Dec 22, 25$12.45Dec 24, 25$12.37Dec 29, 25$12.08Jan 2, 26$11.08Jan 6, 26$11.07Jan 8, 26$10.97Jan 12, 26$10.98Jan 14, 26$12.63Jan 16, 26$13.51Jan 21, 26$13.72Jan 23, 26$12.80Jan 27, 26$11.27Jan 29, 26$10.15Feb 2, 26$9.82Feb 4, 26$9.71Feb 9, 26$9.45Feb 11, 26$9.45Feb 13, 26$8.94Feb 18, 26$9.72Feb 20, 26$11.65Feb 24, 26$12.65Feb 26, 26$12.35Mar 2, 26$11.20Mar 4, 26$11.49Mar 6, 26$12.07Mar 10, 26$12.55Mar 12, 26$11.56Mar 17, 26$11.10Mar 19, 26$10.62Mar 23, 26$11.04Mar 25, 26$11.78Mar 27, 26$15.16Mar 31, 26$18.37Apr 2, 26$19.40Apr 7, 26$19.21Apr 9, 26$19.10Apr 13, 26$17.99Apr 15, 26$19.95Apr 17, 26$21.28Apr 22, 26$26.98Apr 24, 26$24.80Apr 28, 26$23.96Apr 30, 26$22.37May 4, 26$17.92May 6, 26$18.06May 8, 26$18.76May 12, 26$18.46May 14, 26$21.23May 18, 26$18.55May 20, 26$18.91May 22, 26$20.74May 28, 26$21.47Jun 1, 26$19.72Jun 3, 26$17.98Jun 5, 26$18.00Jun 9, 26$18.00Jun 11, 26$18.34Jun 15, 26$18.19Jun 17, 26$18.21Jun 22, 26$17.57Jun 24, 26$17.36Jun 26, 26$18.56Jul 2, 26$17.09
$8.9452-week range$26.98
Loading valuation history…

Fundamentals

Key fundamentals

$598.3M

Market cap

—

Revenue growth (YoY)

100.0%

Gross margin

-$72.5M

Free cash flow (USD)

-$211.5M

Net debt

Net cash position

-46.6%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$18.5KFY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$10.2MFY 2021$1.2MFY 2022$75.0KFY 2023$10.0KFY 2024$0.00FY 2025$10.8M
$18.5K$10.8M

Free cash flow by year

2016 → 2025

FY 2016$-30.4MFY 2017$-30.1MFY 2018$-43.5MFY 2019$-52.1MFY 2020$-39.3MFY 2021$-57.5MFY 2022$-46.5MFY 2023$-34.9MFY 2024$-31.1MFY 2025$-72.5M
-$30.4M-$72.5M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

7

Insider sells · 90 days

Earnings

Last report: 10-Q/A filed Jun 22, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • FinancingSecurities RegistrationJul 1, 2026Filing
  • Insider sellInsider Sell $761K · 10b5-1 PlanBrumm Joshua T · Director, Chief Executive Officer · $761.1KJun 23, 2026Filing
  • Insider sellInsider Sell $370K · 10b5-1 PlanMcNeill Jonathan · President and COO · $369.7KJun 23, 2026Filing
  • Insider sellInsider Sell $22K · 10b5-1 PlanIm Ellie Eunkyung · Chief Medical Officer · $21.9KJun 23, 2026Filing
  • Insider sellInsider Sell $22K · 10b5-1 PlanBispham Barbara Harlin · See Remarks · $21.9KJun 23, 2026Filing
  • Insider sellInsider Sell $20K · 10b5-1 PlanScalzo Richard William · Chief Financial Officer · $20KJun 23, 2026Filing
  • Insider sellInsider Sell $23K · 10b5-1 PlanPinkas Jan · Chief Scientific Officer · $23.2KJun 23, 2026Filing
  • Insider sellInsider Sell $8K · 10b5-1 PlanLynch Ryan · See Remarks · $8.4KJun 23, 2026Filing
  • Quarterly report10-Q FiledJun 22, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 3, 2026Filing

Questions

Frequently asked questions

What is Crescent Biopharma, Inc.'s market cap?

Crescent Biopharma, Inc. (CBIO) has a market capitalization of $598.3M.

What is CBIO's P/E ratio?

A meaningful P/E ratio is not available for CBIO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CBIO's price-to-book (P/B) ratio?

CBIO trades at 2.95 times book value per share.

Are insiders buying CBIO stock?

SEC Form 4 filings show no open-market insider buys at Crescent Biopharma, Inc. in the last 90 days (7 sells).

Same arena

Related companies in Biotechnology

CTMX

CytomX Therapeutics, Inc.

$582.2M

PROK

ProKidney Corp.

$621.5M

GYRE

Gyre Therapeutics, Inc.

$572.7M

ARVN

Arvinas, Inc.

$572M

DNA

Ginkgo Bioworks Holdings, Inc.

$628.4M

PRME

Prime Medicine, Inc.

$632.2M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.